Boxes of the drug mifepristone sit on a shelf at the West Alabama Women’s Center in Tuscaloosa, Ala., on March 16, 2022. (AP Photo/Allen G. Breed, File)

Mail-order access to mifepristone, a Federal Drug Administration-approved abortion pill, will no longer be available, based on a ruling of the U.S. Court of Appeals for the Fifth Circuit.

Circuit Judge Jennifer Walker Elrod delivered the ruling Wednesday in Alliance for Hippocratic Medicine v. Food & Drug Administration, vacating a district court order in part and affirming in part.


NOT FOR REPRINT

© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.